Silo Pharma (SILO) EBT Margin (2019 - 2026)
Silo Pharma (SILO) posted EBT Margin of 9137.45% for Q1 2026, down 86.85% sequentially from 4890.33% in Q4 2025, and down 341551.0% YoY from N/an in Q1 2025.
Silo Pharma (SILO) EBT Margin (2019 - 2026) Analysis & Trends
Silo Pharma has reported EBT Margin for 8 years, with the latest figure at 9137.45% in Q1 2026.
- Quarterly EBT Margin fell 341551.0% year-over-year to 9137.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6717.4% (down 30613.0% YoY) and the FY2025 annual result came in at 5863.5%, up 22909.0% from the prior year.
- EBT Margin retreated to 9137.45% in Q1 2026 per SILO's latest filing, from 4890.33% in the prior quarter.
- Over five years, EBT Margin peaked at 3652.72% in Q2 2022 and troughed at 9600.69% in Q4 2024.
- A 5-year average of 5964.88% and a median of 5537.3% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin tumbled 376703 bps in 2024, then soared 471036 bps in 2025.
- Over 5 years, EBT Margin stood at 9224.63% in 2022, then surged by 37 bps to 5833.66% in 2023, then tumbled by 65 bps to 9600.69% in 2024, then jumped by 49 bps to 4890.33% in 2025, then tumbled by 87 bps to 9137.45% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 9137.45%, 4890.33%, and 6160.54% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Silo Pharma | 2.96 Mn | 2.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,137.45% |
| Dec 31, 2025 | -4,890.33% |
| Sep 30, 2025 | -6,160.54% |
| Jun 30, 2025 | -6,681.24% |
| Mar 31, 2025 | -5,721.94% |
| Dec 31, 2024 | -9,600.69% |
| Sep 30, 2024 | -5,152.92% |
| Jun 30, 2024 | -5,169.37% |
| Mar 31, 2024 | -4,447.28% |
| Dec 31, 2023 | -5,833.66% |
| Sep 30, 2023 | -3,662.47% |
| Jun 30, 2023 | -5,619.70% |
| Mar 31, 2023 | -5,028.27% |
| Dec 31, 2022 | -9,224.63% |
| Sep 30, 2022 | -5,454.90% |
| Jun 30, 2022 | -3,652.72% |
| Jun 30, 2021 | -571.06% |
| Mar 31, 2021 | -1,820.96% |
| Dec 31, 2020 | -2,714.64% |
| Sep 30, 2020 | -3,417.06% |